Cytek Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Cytek Biosciences has a total shareholder equity of $393.1M and total debt of $2.2M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are $494.5M and $101.4M respectively.
Key information
0.6%
Debt to equity ratio
US$2.21m
Debt
Interest coverage ratio | n/a |
Cash | US$262.41m |
Equity | US$393.06m |
Total liabilities | US$101.39m |
Total assets | US$494.46m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: CTKB's short term assets ($392.1M) exceed its short term liabilities ($56.2M).
Long Term Liabilities: CTKB's short term assets ($392.1M) exceed its long term liabilities ($45.2M).
Debt to Equity History and Analysis
Debt Level: CTKB has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CTKB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CTKB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CTKB is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 40.9% per year.